Listener feedback on the nonobstructive HCM trials, AI-enhanced visits, timing of non-culprit PCI in STEMI, new tricuspid valve intervention, and EP at a crossroads are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
Koelemen meta-analysis https://www.medrxiv.org/content/10.64898/2026.09.08.26362195v1.full.pdf
Improving SCD Risk Stratification in HCM https://pmc.ncbi.nlm.nih.gov/articles/PMC11026183/
II More on Nonobstructive HCM
Communication on Post-Hoc Analysis of ODYSSEY (mavacamten)
Mavacamten in Nonobstructive HCM 10.1016/j.jacc.2025.12.092
III Complete vs Staged PCI in STEMI With Multivessel Disease
Immediate vs Staged CR in Multivessel Disease and STEMI: Meta-Analysis https://doi.org/10.1016/j.jcin.2026.07.033
Timing of Nonculprit PCI for STEMI and Multivessel Disease: Editorial https://doi.org/10.1016/j.jcin.2026.08.009
COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775
FLOWER MI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2104650
FRAME AMI Trial https://doi.org/10.1093/eurheartj/ehac763
iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918
COCUA Trial https://doi.org/10.1016/j.ahj.2023.01.020